bluebird bio, Inc. (NASDAQ:BLUE) COO Susanna Gatti High sold 1,282 shares of bluebird bio stock in a transaction on Friday, December 1st. The stock was sold at an average price of $172.15, for a total value of $220,696.30. Following the completion of the sale, the chief operating officer now directly owns 13,718 shares of the company’s stock, valued at approximately $2,361,553.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
bluebird bio, Inc. (BLUE) traded down $3.25 during trading hours on Thursday, hitting $159.40. The company had a trading volume of 976,400 shares, compared to its average volume of 825,955. bluebird bio, Inc. has a 12 month low of $60.95 and a 12 month high of $174.65.
bluebird bio (NASDAQ:BLUE) last posted its earnings results on Wednesday, November 1st. The biotechnology company reported ($1.73) EPS for the quarter, missing analysts’ consensus estimates of ($1.68) by ($0.05). The firm had revenue of $7.71 million during the quarter, compared to analysts’ expectations of $8.47 million. bluebird bio had a negative return on equity of 28.79% and a negative net margin of 883.18%. bluebird bio’s quarterly revenue was up 397.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($2.07) earnings per share. analysts anticipate that bluebird bio, Inc. will post -6.68 EPS for the current fiscal year.
Several brokerages recently commented on BLUE. BidaskClub raised bluebird bio from a “sell” rating to a “hold” rating in a report on Wednesday, August 9th. Morgan Stanley reissued a “hold” rating on shares of bluebird bio in a report on Wednesday, August 9th. Leerink Swann reissued an “outperform” rating and set a $120.00 price target on shares of bluebird bio in a report on Saturday, September 30th. Jefferies Group restated a “buy” rating and issued a $88.00 price objective on shares of bluebird bio in a research report on Friday, August 11th. Finally, Canaccord Genuity began coverage on bluebird bio in a research report on Tuesday. They issued a “buy” rating and a $202.00 price objective on the stock. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and fourteen have assigned a buy rating to the company. bluebird bio presently has a consensus rating of “Buy” and an average price target of $137.57.
WARNING: “Susanna Gatti High Sells 1,282 Shares of bluebird bio, Inc. (BLUE) Stock” was published by Week Herald and is the sole property of of Week Herald. If you are reading this article on another publication, it was stolen and reposted in violation of United States & international copyright laws. The correct version of this article can be viewed at https://weekherald.com/2017/12/07/susanna-gatti-high-sells-1282-shares-of-bluebird-bio-inc-blue-stock.html.
bluebird bio Company Profile
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.